JP2004529118A - インテグリンリガンドを有する酵素活性化細胞分裂停止接合体 - Google Patents

インテグリンリガンドを有する酵素活性化細胞分裂停止接合体 Download PDF

Info

Publication number
JP2004529118A
JP2004529118A JP2002571109A JP2002571109A JP2004529118A JP 2004529118 A JP2004529118 A JP 2004529118A JP 2002571109 A JP2002571109 A JP 2002571109A JP 2002571109 A JP2002571109 A JP 2002571109A JP 2004529118 A JP2004529118 A JP 2004529118A
Authority
JP
Japan
Prior art keywords
substituted
group
unsubstituted
conjugate
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2002571109A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004529118A5 (https=
Inventor
ハンス−ゲオルク・ラーヒェン
イェルク・バウムガルテン
アンドレアス・ショープ
マルクス・アルベルス
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer AG
Original Assignee
Bayer AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer AG filed Critical Bayer AG
Publication of JP2004529118A publication Critical patent/JP2004529118A/ja
Publication of JP2004529118A5 publication Critical patent/JP2004529118A5/ja
Pending legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2002571109A 2001-03-08 2002-03-07 インテグリンリガンドを有する酵素活性化細胞分裂停止接合体 Pending JP2004529118A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP01105350A EP1238678A1 (en) 2001-03-08 2001-03-08 Enzyme-activated cytostatic conjugates with integrin ligands
PCT/EP2002/002501 WO2002072151A1 (en) 2001-03-08 2002-03-07 Enzyme-activated cytostatic conjugates with integrin ligands

Publications (2)

Publication Number Publication Date
JP2004529118A true JP2004529118A (ja) 2004-09-24
JP2004529118A5 JP2004529118A5 (https=) 2005-12-22

Family

ID=8176682

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2002571109A Pending JP2004529118A (ja) 2001-03-08 2002-03-07 インテグリンリガンドを有する酵素活性化細胞分裂停止接合体

Country Status (5)

Country Link
US (2) US7304037B2 (https=)
EP (2) EP1238678A1 (https=)
JP (1) JP2004529118A (https=)
CA (1) CA2439897A1 (https=)
WO (1) WO2002072151A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022506299A (ja) * 2018-11-05 2022-01-17 バイエル ファーマ アクチェンゲゼルシャフト インテグリンリガンドを有する新規な細胞増殖抑制コンジュゲート

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102453036B (zh) * 2010-10-27 2015-12-02 李红玉 一种喜树碱类化合物及其制备方法和在农药中的用途
US9737556B2 (en) 2014-06-13 2017-08-22 Trustees Of Tufts College FAP-activated therapeutic agents, and uses related thereto
CN106573073B (zh) 2014-06-13 2021-09-28 塔夫茨大学信托人 Fap激活的治疗剂以及其相关用途
CN109575051B (zh) * 2019-01-23 2021-07-27 遵义医科大学 一种天然药物成分修饰衍生物及其抗肿瘤应用
US20230293716A1 (en) 2020-05-08 2023-09-21 Bolt Biotherapeutics, Inc. Elastase-substrate, peptide linker immunoconjugates, and uses thereof
WO2023057813A1 (en) 2021-10-04 2023-04-13 Vincerx Pharma Gmbh Compounds, pharmaceutical compositions, and methods for the treatment, prevention, or management of hyperproliferative disorders
WO2023057814A1 (en) 2021-10-04 2023-04-13 Vincerx Pharma Gmbh Compounds, pharmaceutical compositions, and methods for the treatment, prevention, or management of hyperproliferative disorders
WO2023057812A1 (en) 2021-10-04 2023-04-13 Vincerx Pharma Gmbh Compounds, pharmaceutical compositions, and methods for the treatment, prevention, or management of hyperproliferative disorder
JP2025537882A (ja) 2022-11-17 2025-11-20 ハンス-ゲオルク レルケン 腫瘍微小環境において切断可能な小分子-薬物コンジュゲート
GB202407865D0 (en) 2024-06-03 2024-07-17 Elasmogen Ltd Self immolative compounds

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3611194A1 (de) 1986-04-04 1987-10-08 Bayer Ag Cancerostatisches mittel
GB8705477D0 (en) 1987-03-09 1987-04-15 Carlton Med Prod Drug delivery systems
US4975278A (en) 1988-02-26 1990-12-04 Bristol-Myers Company Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells
US4980343A (en) 1988-10-27 1990-12-25 Bayer Aktiengesellschaft Aminooxodihydroisoindoloquinazoline carcinostatic agents
CA2076982A1 (en) 1990-12-27 1992-06-28 Akira Okura Pyridonecarboxylic acid derivatives
US5561116A (en) * 1991-04-11 1996-10-01 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Solid product containing propolis components, and preparation and uses thereof
FR2676058B1 (fr) 1991-04-30 1994-02-25 Hoechst Lab Prodrogues glycosylees, leur procede de preparation et leur utilisation dans le traitement des cancers.
DE4120646A1 (de) 1991-06-22 1992-12-24 Bayer Ag 7-isoindolinyl-chinolon- und naphthyridoncarbonsaeure-derivate
DE4229903A1 (de) 1992-09-08 1994-03-10 Bayer Ag Neue Acetale von Ketophosphamid und Alkylglycosiden
DE4236237A1 (de) 1992-10-27 1994-04-28 Behringwerke Ag Prodrugs, ihre Herstellung und Verwendung als Arzneimittel
US5646159A (en) 1994-07-20 1997-07-08 Research Triangle Institute Water-soluble esters of camptothecin compounds
DE19512484A1 (de) 1995-04-04 1996-10-17 Bayer Ag Kohlenhydratmodifizierte Cytostatika
CA2265484C (en) * 1996-09-10 2008-12-02 The Burnham Institute Tumor homing molecules, conjugates derived therefrom, and methods of using same
ID23424A (id) 1997-05-14 2000-04-20 Bayer Ag Glikokonjugat dari 20(s)-kamptotesin
JP2002510709A (ja) * 1998-04-08 2002-04-09 ジー・ディー・サール・アンド・カンパニー 二重Avb3及び転移関連受容体リガンド
US6291503B1 (en) 1999-01-15 2001-09-18 Bayer Aktiengesellschaft β-phenylalanine derivatives as integrin antagonists
CA2370245A1 (en) * 1999-05-14 2000-11-23 Boehringer Ingelheim Pharmaceuticals, Inc. Enzyme-activated anti-tumor prodrug compounds
ATE438413T1 (de) * 1999-09-08 2009-08-15 Markus Albers Integrin-vermittelte arzneimittel-zielrichtung

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022506299A (ja) * 2018-11-05 2022-01-17 バイエル ファーマ アクチェンゲゼルシャフト インテグリンリガンドを有する新規な細胞増殖抑制コンジュゲート
JP7509768B2 (ja) 2018-11-05 2024-07-02 バイエル ファーマ アクチェンゲゼルシャフト インテグリンリガンドを有する新規な細胞増殖抑制コンジュゲート

Also Published As

Publication number Publication date
EP1238678A1 (en) 2002-09-11
WO2002072151A1 (en) 2002-09-19
US20080108576A1 (en) 2008-05-08
EP1372732A1 (en) 2004-01-02
CA2439897A1 (en) 2002-09-19
US7304037B2 (en) 2007-12-04
US20020193311A1 (en) 2002-12-19

Similar Documents

Publication Publication Date Title
US20080108576A1 (en) Novel cytostatic conjugates with integrin ligands
JP6539729B2 (ja) ペプチド−薬物複合体
EP0950665A1 (en) Modified physiologically active proteins and medicinal compositions containing the same
EP4162955A1 (en) Cnp prodrugs with carrier attachment at the ring moiety
CN104784699A (zh) 叶酸受体结合配体-药物偶联物
TW201004647A (en) Novel dual targeting antitumoural conjugates
AU744425B2 (en) 20(s) camptothecin glycoconjugates
ES2330079T3 (es) Direccionamiento de farmaco mediado par la integrina.
US20020173468A1 (en) Modified cytostatic agents
CA3193485A1 (en) Peptidic conjugates of sn38 useful in the treatment of cancer
CN104906592B (zh) 用于蛋白质药物偶联物的支链联接体
US20020183256A1 (en) Cytostatic-integrin conjugates having specifically cleavable linking units
US20020173452A1 (en) Cytostatic-glycoconjugates having specifically cleavable linking units
US7220824B1 (en) Integrin-mediated drug targeting
HK40090963A (en) Cnp prodrugs with carrier attachment at the ring moiety
CZ401799A3 (cs) Glykokonjugáty 20(S)-camptothecinu, způsob jejich výroby, jejich použití a léčiva tyto látky obsahující
JPWO1998013381A1 (ja) 修飾生理活性蛋白質及びそれを含有する医薬組成物

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20050202

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20050202

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20071218

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20080225

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20080303

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20080408

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20080415

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20080501

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20080512

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080610

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20090217